Matthew T. Wiley's most recent trade in Mind Medicine Inc was a trade of 350,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on March 17, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Mind Medicine Inc | Matthew T. Wiley | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Mar 2025 | 350,000 | 350,000 | - | - | Stock Option (Right to Buy) | |
| BioXcel Therapeutics Inc | Matthew T. Wiley | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Sep 2024 | 21,250 | 25,283 (0%) | 0% | - | Common Stock | |
| BioXcel Therapeutics Inc | Matthew T. Wiley | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 0.55 per share. | 17 Sep 2024 | 6,272 | 19,011 (0%) | 0% | 0.6 | 3,450 | Common Stock |
| BioXcel Therapeutics Inc | Matthew T. Wiley | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Sep 2024 | 750 | 4,248 (0%) | 0% | - | Common Stock | |
| BioXcel Therapeutics Inc | Matthew T. Wiley | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Sep 2024 | 750 | 7,500 | - | - | Restricted Stock Units | |
| BioXcel Therapeutics Inc | Matthew T. Wiley | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 0.69 per share. | 15 Sep 2024 | 215 | 4,033 (0%) | 0% | 0.7 | 149 | Common Stock |
| BioXcel Therapeutics Inc | Matthew T. Wiley | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jul 2024 | 1,875 | 1,875 | - | - | Stock Option (right to buy) | |
| BioXcel Therapeutics Inc | Matthew T. Wiley | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jun 2024 | 750 | 3,742 (0%) | 0% | - | Common Stock | |
| BioXcel Therapeutics Inc | Matthew T. Wiley | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jun 2024 | 750 | 8,250 | - | - | Restricted Stock Units | |
| BioXcel Therapeutics Inc | Matthew T. Wiley | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jun 2024 | 750 | 8,250 | - | - | Restricted Stock Units | |
| BioXcel Therapeutics Inc | Matthew T. Wiley | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 1.26 per share. | 15 Jun 2024 | 244 | 3,498 (0%) | 0% | 1.3 | 308 | Common Stock |
| BioXcel Therapeutics Inc | Matthew T. Wiley | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2024 | 3,000 | 9,000 | - | - | Restricted Stock Units | |
| BioXcel Therapeutics Inc | Matthew T. Wiley | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2024 | 3,000 | 3,000 (0%) | 0% | - | Common Stock | |
| BioXcel Therapeutics Inc | Matthew T. Wiley | CHIEF COMMERCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 2.63 per share. | 15 Mar 2024 | 1,008 | 2,992 (0%) | 0% | 2.6 | 2,656 | Common Stock |
| BioXcel Therapeutics Inc | Matthew T. Wiley | CHIEF COMMERCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2023 | 36,000 | 36,000 | - | - | Stock Option (Right to Buy) | |
| BioXcel Therapeutics Inc | Matthew T. Wiley | CHIEF COMMERCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2023 | 12,000 | 12,000 | - | - | Restricted Stock Units | |
| VYNE Therapeutics Inc | Matthew T. Wiley | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.51 per share. | 30 Jun 2021 | 5,151 | 109,246 (0%) | 0% | 3.5 | 18,080 | Common Stock |
| VYNE Therapeutics Inc | Matthew T. Wiley | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.84 per share. | 31 Mar 2021 | 2,573 | 114,397 (0%) | 0% | 6.8 | 17,599 | Common Stock |
| VYNE Therapeutics Inc | Matthew T. Wiley | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2021 | 64,575 | 64,575 | - | - | Stock Options | |
| VYNE Therapeutics Inc | Matthew T. Wiley | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2021 | 27,675 | 116,970 (0%) | 0% | 0 | Common Stock | |
| VYNE Therapeutics Inc | Matthew T. Wiley | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 1.45 per share. | 30 Nov 2020 | 7,838 | 358,722 (1%) | 0% | 1.4 | 11,326 | Common Stock |
| VYNE Therapeutics Inc | Matthew T. Wiley | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.66 per share. | 30 Sep 2020 | 1,541 | 350,884 (1%) | 0% | 1.7 | 2,558 | Common Stock |